Answers are grounded in this paper and cite their sources.
Clinical review reports clinical presentations and treatment paradigms for pituitary adenomas, highlighting medical therapy for prolactinomas and transsphenoidal surgery for other lesions.
Clinically manifest pituitary adenomas affect approximately 1 in 1100 people and can be complicated by syndromes of hormone excess as well as visual field defects and hypopituitarism from mass effect in larger tumors. First-line therapy for prolactinomas consists of bromocriptine or cabergoline, and transsphenoidal pituitary surgery is first-line therapy for other pituitary adenomas requiring treatment.
No takes yet. Share an insight, caveat, or question.
Tritos et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: